

Arabella Young

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5672137/publications.pdf>

Version: 2024-02-01

22
papers

3,928
citations

361045

20
h-index

676716

22
g-index

23
all docs

23
docs citations

23
times ranked

6819
citing authors

#	ARTICLE	IF	CITATIONS
1	At the Heart of Immune Checkpoint Inhibitorâ€“Induced Immune Toxicity. <i>Cancer Discovery</i> , 2021, 11, 537-539.	7.7	2
2	Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. <i>Trends in Immunology</i> , 2021, 42, 293-311.	2.9	62
3	Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. <i>Science Immunology</i> , 2020, 5, .	5.6	148
4	Breaking β^2 Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapyâ€“Induced Diabetes Mellitus. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa114.	0.1	3
5	Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies. <i>Frontiers in Immunology</i> , 2020, 11, 1633.	2.2	26
6	A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. <i>Cancer Research</i> , 2018, 78, 1003-1016.	0.4	269
7	The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. <i>Cancer Immunology Research</i> , 2018, 6, 1445-1452.	1.6	132
8	Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. <i>Diabetes</i> , 2018, 67, 1471-1480.	0.3	386
9	Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. <i>Cell Reports</i> , 2018, 23, 3262-3274.	2.9	207
10	G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 7077-7082.	3.3	105
11	Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. <i>Nature Immunology</i> , 2017, 18, 1004-1015.	7.0	504
12	MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. <i>Cancer Research</i> , 2017, 77, 4697-4709.	0.4	126
13	Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. <i>Cancer Research</i> , 2017, 77, 4684-4696.	0.4	80
14	Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. <i>Cancer Research</i> , 2016, 76, 4372-4382.	0.4	130
15	Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses. <i>Cancer Cell</i> , 2016, 30, 391-403.	7.7	300
16	Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. <i>Cancer Discovery</i> , 2016, 6, 1382-1399.	7.7	592
17	Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cellâ€“Rich Tumor. <i>Cancer Research</i> , 2016, 76, 6266-6277.	0.4	74
18	A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. <i>Cancer Research</i> , 2015, 75, 3800-3811.	0.4	201

#	ARTICLE	IF	CITATIONS
19	NK cells require IL-28R for optimal in vivo activity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2376-84.	3.3	82
20	Co-blockade of immune checkpoints and adenosine A _{2A} receptor suppresses metastasis. OncoImmunology, 2014, 3, e958952.	2.1	22
21	Targeting Cancer-Derived Adenosine:New Therapeutic Approaches. Cancer Discovery, 2014, 4, 879-888.	7.7	256
22	Antimetastatic Effects of Blocking PD-1 and the Adenosine A _{2A} Receptor. Cancer Research, 2014, 74, 3652-3658.	0.4	217